ACC: AZ's Farxiga shows CV benefits regardless of prior therapy by Kyle Blankenship Saturday, March 28, 2020 AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.
FDA blocks Lilly, Boehringer's Jardiance in Type 1 diabetes by Kyle Blankenship Monday, March 23, 2020 Boehringer and Lilly's Jardiance is locked in a Type 2 diabetes battle against its SGLT2 rivals, and a leg up in Type 1 now doesn't appear likely.
AstraZeneca's tremelimumab misses again, this time in SCLC by Carly Helfand Tuesday, March 17, 2020 Here’s a familiar sentence: A combo of Imfinzi and tremelimumab missed its primary endpoint. This time, it applies to a small-cell lung cancer trial.
Lilly, BI's Jardiance nabs speedy FDA review in kidney disease by Kyle Blankenship Thursday, March 12, 2020 Aiming to keep pace with its SGLT2 rivals in kidney disease, Lilly and Boehringer's Jardiance scored a speedy FDA review in the indication.
AstraZeneca CEO Soriot scored $18.5M in 2019, a 26% pay hike by Kyle Blankenship Wednesday, March 11, 2020 For AstraZeneca, 2019 was the year of the rebrand as it pivoted to cancer and rare diseases—and that shift yielded its CEO a 26% raise.
Imfinzi's first nod in danger after bladder cancer trial failure by Angus Liu Friday, March 6, 2020 Imfinzi, given alone or in tandem with AZ's troubled CTLA4 tremelimumab, failed against chemo in first-line bladder cancer.
AstraZeneca hawks suite of hypertension drugs for $350M by Kyle Blankenship Monday, March 2, 2020 Doubling down on its asset-sale streak, AstraZeneca pawned off five of its hypertension meds to Atnahs Pharma for an upfront payment of $350 million.
AbbVie, GSK, Sanofi and more set COVID-19 travel restrictions by Angus Liu Friday, February 28, 2020 Several Big Pharma companies have either prohibited travel to and from China or postponed business meetings in affected areas.
Harvard-GIRH, GSK-Clover, Vir-WuXi and more—FiercePharmaAsia by Angus Liu Friday, February 28, 2020 Several influential institutions and biopharma companies have joined hands in developing COVID-19 therapies. Takeda's buying PvP for $330 million.
Lilly's Cyramza narrowly wins lung cancer backing from FDA panel by Arlene Weintraub Thursday, February 27, 2020 An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.
